Malignant Thoracic Neoplasm

In analysis of LUX-Lung 3 and LUX-Lung 6 trials (NCT00949650 and NCT01121393), of EGFR mutant NSCLC, median overall survival with afatinib treatment was seen to be significantly improved over chemothe… (full text at CIViC)

PMID 25589191 · Yang et al., 2015 · Open in CIViC

In a phase 2 study (NCT00525148), patients with lung adenocarcinoma (stage IIIb with pleural effusion or stage IV) and EGFR mutations, treated with afatinib, were assessed by objective response. In to… (full text at CIViC)

PMID 22452895 · Yang et al., 2012 · Open in CIViC

Stable HEK293 cell lines expressing mutant EGFR cDNAs were created (using a pQCLIN retroviral vector) and their drug sensitivities to afatinib were examined by MTT assay. Phorphorylation of EGFR was a… (full text at CIViC)

PMID 25862853 · Banno et al., 2015 · Open in CIViC

Cells harboring an exon 19 deletion were sensitive to afatinib. This study performed drug response assays using five human NSCLC cell lines with various combinations of EGFR mutations. In order to dir… (full text at CIViC)

PMID 26515464 · Hirano et al., 2015 · Open in CIViC

A patient with stage IVA lung adenocarcinoma harboring an EGFR exon 19 deletion developed acquired resistance to osimertinib without an identified molecular resistance mechanism. The patient subsequen… (full text at CIViC)

PMID 40959071 · Fu et al., 2025 · Open in CIViC

In a multicenter retrospective study, the relationship between EGFR status in 171 patients with non-small cell lung carcinoma and response to immune checkpoint blockade was examined. Immune checkpoint… (full text at CIViC)

PMID 31086949 · Hastings et al., 2019 · Open in CIViC

In a multicenter retrospective study, the relationship between EGFR status in 171 patients with non-small cell lung carcinoma and response to immune checkpoint blockade was examined. Immune checkpoint… (full text at CIViC)

PMID 31086949 · Hastings et al., 2019 · Open in CIViC

Non-small cell cancer patients from two studies [The ARCHER 1009 (NCT01360554) and A7471028 (NCT00769067)] with exon 19 deletion and L858R EGFR (Exon 21) mutations were pooled to compare the efficacy … (full text at CIViC)

PMID 26768165 · Ramalingam et al., 2016 · Open in CIViC

Deguelin exhibits a potent inhibitory effect in gefitinib-sensitive HCC827 cells with exon 19 deletion (EGFR E746-A750). Both deguelin and gefitinib significantly suppressed EGFR kinase activity, redu… (full text at CIViC)

PMID 32081857 · Gao et al., 2020 · Open in CIViC

On May 14, 2013, the U.S. Food and Drug Administration approved erlotinib (Tarceva) for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epider… (full text at CIViC)

PMID 24868098 · Khozin et al., 2014 · Open in CIViC

A randomized phase 3 trial involving 173 NSCLC patients with EGFR mutations (exon 19 deletion or L858R mutation in exon 21) with no history of chemotherapy for metastatic disease. Patients were random… (full text at CIViC)

PMID 22285168 · Rosell et al., 2012 · Open in CIViC

In a stage IV lung adenocarcinoma patient harboring EGFR exon 19 deletion, EGFR exon 19 deletion was associated with sensitivity to erlotinib monotherapy. Prior to identification of the EGFR exon 19 d… (full text at CIViC)

PMID 27566387 · Kanemaru et al., 2016 · Open in CIViC

90 NSCLC patients with stage IIIB/IV chemotherapy-resistant tumors were treated with gefitinib, and exon 19 deletion of EGFR was associated with longer time to treatment failure than those with wild-t… (full text at CIViC)

PMID 18509184 · Yang et al., 2008 · Open in CIViC

In a phase 3 clinical trial of Korean, never-smoker, lung adenocarcinoma patients, a subset of patients with EGFR mutations (n=42) treated with gefitinib were associated with improved overall response… (full text at CIViC)

PMID 22370314 · Han et al., 2012 · Open in CIViC

A Japanese Phase III clinical study assessed the noninferiority of gefitinib in comparison to erlotinib in 561 patients with postoperative or recurrent stage IIIB/IV lung adenocarcinoma. Patients were… (full text at CIViC)

PMID 27022112 · Urata et al., 2016 · Open in CIViC

Exon 19 deletion has been shown to be correlated with gefitinib response.

PMID 16730237 · Ji et al., 2006 · Open in CIViC

NSCLC patients with exon 19 deletions in EGFR had longer overall survival than patients with an L858R mutation when treated with gefitinib or erlotinib (38 versus 17 months; P = 0.04).

PMID 16818686 · Jackman et al., 2006 · Open in CIViC

The goal of this study was to assess the frequency, overall survival, and classifying actionability of EGFR mutations in NSCLC within the Dutch population from 2013-2017. This study found that despite… (full text at CIViC)

PMID 34298851 · Koopman et al., 2021 · Open in CIViC

A 53-year old woman (former smoker: 15 pack-years) was diagnosed with non-small-cell lung cancer that revealed an adenocarcinoma. Initial tumor was sequenced to find an EGFR exon 19 deletion mutation … (full text at CIViC)

PMID 30341016 · Kauffmann-Guerrero et al., 2019 · Open in CIViC

A 65-year old female diagnosed with lung adenocarcinoma revealed several brain lesions, the largest measuring 1.8 x 1.5 x 1.9 cm. COBAS EGFR mutation test was run and revealed EGFR exon 19 deletion mu… (full text at CIViC)

PMID 36188633 · Wilgucki et al., 2022 · Open in CIViC

In retrospective analysis of trials, afatinib conferred limited clinical benefit to patients with EGFR exon 20 insertion mutations (N=23). Only 2 patients had objective responses.

PMID 26051236 · Yang et al., 2015 · Open in CIViC

In this phase 1, open-label, dose-escalation trial, 81 patients with NSCLC involving an EGFR exon 20 insertion in phase 2 of the study were administered 1,050 mg amivantamab (1,400 mg if > 80 kg) give… (full text at CIViC)

PMID 34339292 · Park et al., 2021 · Open in CIViC

A phase 3 study of 889 advanced non-small cell lung cancer patients (with non-progressive disease while on standard chemotherapy treatment), reported that patients harboring EGFR mutation (exon 19 del… (full text at CIViC)

PMID 21969500 · Brugger et al., 2011 · Open in CIViC

Double blind Phase II clinical trial evaluated 208 patients for efficacy of gefitinib against non-small cell lung cancer. For individuals taking 250mg/day, they observed an objective response rate of … (full text at CIViC)

PMID 12748244 · Fukuoka et al., 2003 · Open in CIViC

A single case with EGFR(ex24)::FGFR1(ex10) was identified in a large study of 3505 EGFR(del19, L858R, G719*, S768I, and L851Q)-positive NSCLC cases. The goal of the study was to analyze the role of co… (full text at CIViC)

PMID 29883838 · Schrock et al., 2018 · Open in CIViC

In this phase 2 study, 129 patients with NSCLC, including those with less common, non-resistant EGFR mutations such as S768I, L861Q, and/or G719X, were treated with afatinib in two cohorts: 99 with a … (full text at CIViC)

PMID 22452895 · Yang et al., 2012 · Open in CIViC

In a meta-analysis of 7 clinical trials of erlotinib (some vs placebo or other treatment), 10/24 patients with Exon 18 mutations harbored a G719 variant. These variants were associated with improved p… (full text at CIViC)

PMID 26773740 · Klughammer et al., 2016 · Open in CIViC

In a study of 889 non-small cell lung cancer patients, mutations in the EGFR gene was observed in 11.1% of patients (58 of 518 sequenced). Patients with an EGFR mutation were associated with an improv… (full text at CIViC)

PMID 20493771 · Cappuzzo et al., 2010 · Open in CIViC

3 patients with stage IV non small cell lung adenocarcinoma with G719A mutation were given erlotinib. 1 patient was alive at end of study with progression free survival (PFS) of 27.2 months and overal… (full text at CIViC)

PMID 21531810 · Wu et al., 2011 · Open in CIViC

Stage IIIB/IV patients with histologically proven NSCLC were enrolled in this study if the tumor cells bore EGFR mutations other than T790M. Patient with E709K and G719A demontrates PR and an early … (full text at CIViC)

PMID 25179728 · Chang et al., 2015 · Open in CIViC

A 60-year old man (smoker: 300 pack-years) presented with lung adenocarcinoma measuring 3.0 x 2.3 cm and multiple lymph node metastases. Next-generation sequencing revealed a EGFR G719A (abundance 5.0… (full text at CIViC)

PMID 30922580 · Zeng et al., 2019 · Open in CIViC

A patient with stage IV lung squamous cell carcinoma harboring an EGFR G719C mutation and high PD-L1 expression (tumor proportion score of 90%) experienced disease progression after 1.5 months of afat… (full text at CIViC)

PMID 40959071 · Fu et al., 2025 · Open in CIViC

The E709A+G719C double mutation was found in an 80-year-old female never smoker with advanced adenocarcinoma of the lung with acinar and BAC characteristics. Erlotinib was given at the starting dose o… (full text at CIViC)

PMID 21841502 · De Pas et al., 2011 · Open in CIViC

In a study, 2 participants with stage IV lung adenocarcinoma were sequenced at EGFR exons 18 to 21. Both patients were found to have G719D mutation and were treated with the 1st generation TKIs gefiti… (full text at CIViC)

PMID 21531810 · Wu et al., 2011 · Open in CIViC

The G719S mutation was found in a 50-year-old female never smoker with advanced adenocarcinoma of the lung. One month after the end of chemotherapy, , she started erlotinib at 150 mg/d. At the first c… (full text at CIViC)

PMID 21841502 · De Pas et al., 2011 · Open in CIViC